Fenoterol: Pharmacology and clinical use

Cardiovascular Drug Reviews

Volumn 17, Issue 1, 1999, Pages 87-106

  Gleiter, C H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Clinical use; Fenoterol; Pharmacology; 2 Adrenoceptor agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL;

BRONCHODILATATION; DRUG SAFETY; DRUG USE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TACHYCARDIA;

EID: 0032786538     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00006.x     Document Type: Review

References (139)

1. Allon M, Duntay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med 1989;110:426-429.
2. Arndts D, Notman J, Rominger K. Untersuchungen zum Ausschuß der fetalen Kardiotoxizität bei der Ratte. In: Jung H, Friedrich E, eds. Fenoterol (Partusisten®) bei der Behandlung in der Geburtshilfe und Perinatologie. Stuttgart, Germany:Thieme, 1978;201.
3. Babenerd J, Flehr I. Mütterliche Zwischenfälle unter Tokolyse mit Fenoterol. Med Welt 1979;30:537-541.
4. 2 adrenergic receptors in asthma: a current perspective. Lung 1992;170;125-141.
5. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996;42:3-10.
6. Bauer KG, Kaik B, Sertl K, Kaik GA. Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalemic effects of fenoterol dry powder in asthma. Br J Clin Pharmacol 1993;36:285-292.
7. Behrens C, Fallenstein F, Koch K, Spätling L. Ein neuer Ansatz zur Optimierung der Dosierung bei pulsatiler Bolustokolyse. Geburtsh u Frauenheilk 1998;58:251-256.
8. Berg G, Andersson RGG, Ryden G. Beta-adrenoceptor function of leukocytes in pregnant women treated with terbutaline for preterm labor. Acta Obstet Gynecol Scand 1984;63:555-561.
9. Bia MJ, Lu D, Tyler K, De Fronzo RA. Beta adrenergic control of extrarenal potassium disposal. Nephron 1986;43:117-122.
10. Böhm N, Adler CP. Focal necroses, fatty degeneration and subendocardial nuclear polyploidization of the myocardium in newborns after beta-sympathomimetic suppression of premature labor. Eur J Pediatr 1989;136:149-157.
11. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. New Engl J Med 1990; 323:1033-1039.
12. Bouillon T, Meineke I, Port R, Hildebrandt R, Günther K, Gundert-Remy U. Concentration-effect relationship of the positive chronotropic and hypokalemic effects of fenoterol in healthy women of childbearing age. Eur J Clin Pharmacol 1996;51:153-160.
13. Boulton DW, Fawcett JP. Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol 1996;14:115-138.
14. Brodde O, Brinkmann M, Schemuth R, O'Hara N, Daul A. Terbutaline-induced desensitization of human lymphocyte beta2 adrenoceptors. J Clin Invest 1985;76:1096-1101.
15. 2-receptor stimulation by circulating epinephrine. New Engl J Med 1983;309:1414-1419.
16. 2 receptor stimulation by circulating epinephrine. Am J Cardiol 1985; 56:3D-9D.
17. Buchelt L, Rominger KL. The pharmacokinetics and metabolism of Berotec (fenoterol) in man. Med Proc 1972;18:15-20.
18. Buchelt L, Rominger KL. Pharmakokinetik und Metabolismus von Th 1165. A beim Menschen. Int J Clin Pharmacol 1972;4(Suppl):37-41.
19. 2-adrenoceptor agonists. Eur J Clin Pharmacol 1989;36: 415-417.
20. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985;132:541-547.
21. Casper RF, Lye SJ. Myometrial desensitization to continuous but not to intermittent beta-adrenergic agonist infusion in the sheep. Am J Obstet Gynecol 1986;154:301-305.
22. 2-agonist. Clin Pharmacol Ther 1984;35:762-767.
23. + transport and membrane potential in rat soleus muscle. J Physiol 1977;270:383-414.
24. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989;44:136-140.
25. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: a case control study. Lancet 1989;I:917-922.
26. Crane J, Burgess C, Pearce N, Beasley R, Jackson R. Asthma deaths in New Zealand, Br Med J 1992; 304:1307.
27. Davis C, Conolly ME. Tachyphylaxis to beta-adrenoceptor agonists in human bronchial smooth muscle: studies in vitro. Br J Clin Pharmacol 1980;10:417-421.
28. D'Silva JL. The action of adrenaline on serum potassium. J Physiol 1934;82:393-398.
29. Dudenhausen JW, Hermer M, Rominger KL. Mütterliche Plasmakonzentrationen bei multipler oraler Fenoterolbehandlung. Geburtsh Frauenheilk 1989;49:234-236.
30. 2-adrenoceptors in guinea pig and human lung. Postgrad Med J 1981;57(suppl 1):77-83.
31. Engelhardt S, Zieger W, Kassubek J, Michel MC, Lohse MJ, Brodde OE. Tocolytic therapy with fenoterol induces selective down-regulation of β-adrenergic receptors in human myometrium. J Clin Endocrinol Metab 1997;82:1235-1242.
32. Epstein MF, Nichols E, Stubblefield PG. Neonatal hypoglycemia after beta-sympathomimetic tocolytic therapy. J Pediatr 1979;94:449-453.
33. Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J. The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline. Chest 1989;96:1317-1320.
34. Fletcher SE, Fyfe DA, Case CL, Wiles HB, Upshur JK, Newman B. Myocardial necrosis in a newborn after long-term maternal subcutaneous terbutaline infusion for suppression of preterm labor. Am J Obstet Gynecol 1991;165:1401-1404.
35. Freyz H, Willard D, Lehr A, Messer I, Boog G. A long term evaluation of infants who received a beta-mimetic drug while in utero. J Perinat Med 1977;5:94-99.
36. Fuller RW. The asthma death problem revisited. Br J Clin Pharmacol 1996;42:11-14.
37. Garrett JE, Kolbe J, Richards G, Whitlock RML, Rea HH. Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned? Thorax 1995;50:303-311.
38. Garrett J, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and beta-agonist type: an example of confounding by severity. Thorax 1996;51:1093-1099.
39. Garrett JE, Lanes S, Rea HH, Kolbe J, Fenoterol, asthma deaths, and asthma severity: confounding or confusion. Reply. Thorax 1997;52:750-752.
40. Gerhard I, Henninger R, von Holst T, Runnebaum B, Kubli F. Wehenhemmung mit Fenoterol. II Bedeutung von Beginn, Dauer und Art der Therapie für den Zustand des Neugeborenen und die frühkindliche Entwicklung bis zu vier Jahren. Z Geburtsh Perinat 1989;193:51-59.
41. Gleiter CH, Becker T, Schreeb KH, Freudenthaler S, Gundert-Remy U. Fenoterol but not dobutamine increases erythropoietin production in humans. Clin Pharmacol Ther 1997;61:669-676.
42. Gleiter CH, Schreeb KH, Goldbach S, Herzog S, Cunze T, Kuhn W. Fenoterol increases erythropoietin concentrations during tocolysis. Br J Clin Pharmacol 1998;45:(in press).
43. Groome LJ, Goldenberg RL, Cliver SP, et al. Neonatal periventricular-intraventricular hemorrhage after maternal beta-sympathomimetic tocolysis. Am J Obstet Gynecol 1992;167:873-879.
44. Grospietsch G, Fenske M, Dietrich B, Ensink FBM, Hölzl M, Kuhn W. Effect of the tocolytic agent fenoterol on body weight, urine excretion, serum protein, and electrolyte levels in nonpregnant rabbits. Am J Obstet Gynecol 1982;143:667-672.
45. Gumei AM, Miller WS, Miller J. Bronchodilator effect of a new oral beta-adrenoceptor stimulant Th 1165a. A comparison with metaproterenol sulphate. Chest 1976;70:460-465.
46. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. New Engl J Med 1991;325:388-392.
47. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New Engl J Med 1994;331:700-705.
48. Haalboom JRE, Deenstra M, Struyvenberg A. Hypokalemia induced by inhalation of fenoterol. Lancet 1985;I:1125-1127.
49. 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan. Can Med Assoc J 1995;153:1437-1443.
50. Hadcock JR, Malbon CC. Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels. Proc Natl Acad Sci USA 1988;85:5021-5025.
51. Hadders-Alqra M, Touwen BCL, Huisjes HJ. Long-term follow up of children prenatally exposed to ritodrine. Br J Obstet Gynaecol 1986;93:156-161.
52. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213-1214.
53. Hammermaier A, Bidlingmaier A, Waitzinger J, Stechert R, Wenske H, Jaeger H. Radiolabelling of drugs in a metered dose inhaler (MDI) and lung disposition in human subjects. J Aerosol Med 1994;7:173-176.
54. 2-agonist therapy in asthma. Eur Respir J 1988;11:589-593.
55. Hasaart THM, de Haan J. Effect of continuous infusion of fenoterol on maternal pelvic and fetal umbilical blood flow in pregnant sheep. J Perinat Med 1987;15:523-529.
56. 2-adrenergic receptor. Symp Soc Exp Biol 1990; 44:225-240.
57. 2-sympathomimetic treatment of premature labour. Anaesth Intens Care 1984;12:143-151.
58. Heel RC, Bogden RN, Speight TM, Avery GS. Fenoterol: A review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1978;15:3-23.
59. Higgins RM, Cookson WOCM, Lane DG, John SM, McCarthy GL. Cardiac arrhythmias caused by nebulized beta-agonist therapy. Lancet 1987;II:863-864.
60. Hildebrandt R, Weitzel H, Warnke K, Gundert-Remy U. Pharmacokinetics of fenoterol in pregnant and nonpregnant women. Eur J Clin Pharmacol 1993;45:275-277.
61. Hildebrandt R, Wagner B, Preiss-Nowzohour K, Gundert-Remy U. Fenoterol metabolism in man: sulphation versus glucuronidation. Xenobiotica 1994;24:71-77.
62. Hochhaus G, Schmidt EW, Rominger KL, Möllmann H. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res 1992;9:291-297.
63. 2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 1992;9:342-362.
64. Jonkers R, van Boxtel CJ, Ooosterhuis B. Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol. Clin Pharmacol Ther 1987;42:627-633.
65. Kaiser G, Wiemer G, Kremer G, Dietz J, Palm D. Identification and quantification of beta-adrenoceptor sites in red blood cells from rats. Naunyn Schmiedeberg's Arch Pharmacol 1978;305:41-50.
66. Kast A, Tsunenari Y, Honma M, Nishikawa J, Shibata T, Torii M. Acute, subacute and chronic toxicity studies of the beta-sympathomimetic fenoterol HBr on rats, mice and rabbits. Pharmacometrics 1975:10;45.
67. Kast A, Tsunenari Y, Honma M, Iida H. Cardiac effects of fenoterol hydrobromide on newborn versus adult rats. Arzneim Forsch Drug Res 1985;35:188-192.
68. Kast A, Hermer M. Beta-adrenoceptor tocolysis and effects on the heart of fetus and neonate. A review. J Perinat Med 1993;21:97-106.
69. Ke R, Vohra M, Casper R. Prolonged inhibition of human myometrial contractility by intermittent isoproterenol. Am J Obstet Gynecol 1984;149:841-844.
70. Kemp JP, Meltzer EO. Beta2 adrenergic agonists - oral or aerosol for the treatment of asthma? J Asthma 1990;27:149-157.
71. Keirse M, Grant A, King J. Preterm labor. In: Chalmers J, Enkin M, Keirse M, eds. Effective care in pregnancy and childbirth. Oxford: Oxford University Press, 1989;694-745.
72. King JF, Grant AM, Keirse MJNC, Chalmers I. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988;95:211-222.
73. Kojima S, Otani M, Kubodera A. Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165a, fenoterol hydrobromide) in mice. Arzneim Forsch Drug Res 1980;30:959-964.
74. Koster AS, Hofman GA, Frankhuijzen-Sierevogel AC, Noordhoek J. Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. Drug Metab Dispos 1985;13:464-470.
75. Lanes SF, Birmann B, Raiford D, Walker AM. International trends in sales of inhaled fenoterol, all inhaled β agonists, and asthma mortality, 1970-1992. J Clin Epidemiol 1997;50:321-328.
76. Larsson S. Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance and routes of administration. Acta Med Scand 1977;202(Suppl 608):1-40.
77. Laursen LC, Taudorf E, Gnosspelius Y, Gymose E, Weeke B. Long-term oral therapy of asthma with terbutaline and theophylline, alone and combined. Eur J Respir Dis 1985;66:82-90.
78. Lefkowitz RJ, Hoffman BB, Taylor P. Neurotransmission. The autonomie and somatic motor nervous systems. In: Hardman, JG, et al. eds. Goodman-Gilman's The pharmacological basis of therapeutics. New York: MacGraw-Hill, 1996;105-139.
79. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not airways responses during prolonged therapy with high dose inhaled salbutamol. Am Rev Respir Dis 1989;140:586-592.
80. Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments hypokalemic and electrocardiographic effects of albuterol. Am J Med 1989;86:653-657.
81. Lipworth BJ, McDevitt DG. Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance? Br J Clin Pharmacol 1992;33:129-138.
82. Lipworth BJ, Newnham DM, Clark RA. Dhillon DP, Winter JH, McDevitt DG. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50:54-61.
83. Lulich KM, Goldie RG, Ryan G, Paterson JW. Adverse reactions to beta2-agonist bronchodilators. Med Toxicol 1986;1:286-299.
84. Mahon WA, Reid DWJ, Day RA. The in vivo effects of beta-adrenergic stimulation and blockade on the human uterus at term. J Pharmacol Exp Ther 1967;156:178-185.
85. von Mandach U, Huch A, Huch R. Pharmacokinetic studies on fenoterol in maternal and cord blood. Am J Perinatol 1989;6:209-213.
86. von Mandach U, Böni R, Danko J, Huch R, Huch A. Pharmacokinetics of fenoterol in pregnant women. Arzneim Forsch Drug Res 1995;45:186-189.
87. McFadden Jr ER. The beta2-agonist controversy revisited. Ann Allergy Asthma Immunol 1995;75:173-176.
88. Meinen K, Stofft E, Valder WA, Breinl H. Zur Kardiotoxizität des Fenoterol - Ultramorphologische und morphometrische Untersuchungen am Kaninchenmyokard. Geburtsh Perinat 1983;187:218-225.
89. 2 adrenergic tocolytic therapy: Correlation with lymphocyte beta adrenoceptors. Clin Pharmacol Ther 1989;45:1-8.
90. Minette A. Spirometric study of the bronchodilating effect of hydroxyphenylorciprenaline (Th 1165a) in various forms in a group of 124 coal miners suffering from bronchospasm. Respiration 1970;27:276-315.
91. Montoliu J, Almirall J, Ponz E, et al. Treatment of hyperkalemia in renal failure with salbutamol inhalation. J Intern Med 1990;228:35-37.
92. Moutquin JM, et al. Treatment of preterm labor with beta-adrenergic agonist ritodrine. New Engl J Med 1992;327:308-312.
93. Muacevic G. Determination of bioavailability on the basis of tachycardia after intravenous and oral administration of fenoterol, orciprenaline and salbutamol in non-anaesthetized rats. Arzneim Forsch Drug Res 1985;35:406-408.
94. Musch W, Vincken W, Noppen M, Gorus F. Metabolic effects of inhaled fenoterol in normal subjects. Chest 1992;102:1099-1103.
95. Nadel JA, Barnes PJ. Autonomic regulation of the airways. Ann Rev Med 1984;35:451-467.
96. Nelson HS. Beta-adrenergic bronchodilators. New Engl J Med 1995;333:499-506.
97. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996;110:595-603.
98. 2, activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 1993;48:656-658.
99. NIH International Report: International consensus report on diagnosis and treatment of asthma. 1992; Publication No. 92-3091.
100. O'Donnell SR. A selective beta-adrenoceptor stimulant (Th 1165a) related to orciprenaline. Eur J Pharmacol 1970;12:35-43.
101. O'Donnell SR. An examination of some beta adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea pig. Eur J Pharmacol 1972;19:371-379.
102. O'Donnell SR, Wanstall JC. Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta adrenoceptors in guinea pig trachea. Eur J Pharmacol 1978;47:333-340.
103. 2 agonists. Lancet 1991;337:717-720.
104. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-44.
105. Pearce N, Burgess C, Crane J, Beasley R. Fenoterol, asthma deaths, and asthma severity: confounding or confusion? Thorax 1997;52:750-752.
106. Pearce N, Crane J, Beasley R. Time trends in fenoterol and asthma deaths: Optical illusion or reality check? J Clin Epidemiol 1998;51:633-634.
107. Pisani RJ, Rosenow EC. Pulmonary edema associated with tocolytic therapy. Ann Intern Med 1989;110: 714-718.
108. 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-339.
109. Rodenstein D, Stanescu DC. Mouth spraying versus inhalation of fenoterol aerosol in healthy subjects and asthmatic patients. Br J Dis Chest 1982;76:365-373.
110. Rominger KL, Pollmann W. Vergleichende Pharmakokinetik von Fenoterol-hydrobromid bei Ratte, Hund and Mensch. Arzneim Forsch Drug Res 1972;22:1190-1196.
111. Rominger KL, Albert HJ. Radioimmunological determination of fenoterol. Part I: Theoretical fundamentals. Arzneim Forsch Drug Res 1985;35:415-420.
112. Rominger KL, Hermer M. Neuere Ergebnisse zur Pharmakokinetik von Fenoterol. In: Jung H, Fendel H, Karl C, eds. Neueste Ergebnisse über Betamimetika. Darmstadt: Steinkopff, 1986.
113. Rominger KL, Mentrup A, Stiasni M. Radioimmunological determination of fenoterol. Part II: Antiserum and tracer for the determination of fenoterol. Arzneim Forsch Drug Res 1990;40:887-895.
114. van Schayck CP, Dompeling E, van Heerwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. Br Med J 1991;303: 1426-1431.
115. Scheinin M, Koulu M, Laurikainen E, Allonen H. Hypokalemia and other non-bronchial effects of inhaled fenoterol and salbutamol: A placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 1987;24:645-653.
116. Schmekel B, Boergström L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and nonsmokers. Thorax 1991;46:225-228.
117. 2agonists (in the light of fenoterol). Respiration 1995;62:190-200.
118. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-1396.
119. Sears MR, Taylor DR. The beta2 agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Safety 1994;11:259-283.
120. Sibley DR, Lefkowitz RJ. Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a modulator. Nature 1985;317:124-129.
121. Spätling L, Fallenstein F, Schneider H, Dancis J Bolustocolysis. Treatment of preterm labour with pulsatile administration of beta-adrenergic agonist. Am J Obstet Gynecol 1989;160:713-717.
122. Spitzer WO, Suissa S, Ernst P, et al. The use of beta agonists and the risk of death and near death from asthma. New Engl J Med 1992;326:501-506.
123. 1 receptors in the hemodynamic response to a beta-2 agonist. Clin Pharmacol Ther 1986;40:108-115.
124. Stix I, Dressler F, Saling E. Untersuchungen der kardialen Spätfolgen bei Kindern nach Langzeittokolyse mit Fenoterol und Verapamil. Geburtsh Frauenheilk 1982;42:857-861.
125. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β agonists. Am J Respir Crit Care Med 1994;149:604-610.
126. Suissa S, Ernst P. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic. J Clin Epidemiol 1997;50:1079-1088.
127. Suissa S, Ernst P. Response. J Clin Epidemiol 1998;51:634-635.
128. Svedmyr N. Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1985;5:109-126.
129. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 1997;350: 995-999.
130. Tandon MK. Cardiopulmonary effects of fenoterol and salbutamol aerosol. Chest 1980;77:429-431.
131. Taylor DR, Wilkens GT, Herbison GP, Flannery EM. Interaction between corticosteroid and beta-agonist drug. Chest 1992;102:519-524.
132. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-138.
133. Torphy T. Beta-adrenoceptors, cAMP and air way smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994;15:370-374.
134. 2-adrenergic receptor in nocturnal and nonnocturnal asthma. J Clin Invest 1995;95:1635-1641.
135. Vaisman N, Koren G, Goldstein D, et al. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 1987;111:914-917.
136. Wachs T, Sheppard RL, Henion J. Design and applications of a self-aligning liquid junction - electrospray interface for capillary electrophoresis-mass spectrometry. J Chromatography B 1996;685:335-342.
137. 1-adrenoceptor agonist fenoterol in healthy women. Eur J Clin Pharmacol 1992;43:663-665.
138. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet 1981;I:1235-1327.
139. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990;336:1396-1399.